127 related articles for article (PubMed ID: 29619509)
1. Interferon-α2b-induced STAT3 suppression in myeloid-derived suppressor cells in mycosis fungoides.
Geskin LJ; Akilov OE; Schowalter MK; Falo LD
Cancer Immunol Immunother; 2018 Jul; 67(7):1177-1178. PubMed ID: 29619509
[No Abstract] [Full Text] [Related]
2. The role of myeloid derived suppressor cells in mycosis fungoides.
Pileri A; Agostinelli C; Quaglino P; Patrizi A; Pimpinelli N
Cancer Immunol Immunother; 2018 Jul; 67(7):1175-1176. PubMed ID: 29574491
[No Abstract] [Full Text] [Related]
3. [Folliculotropic mycosis fungoides].
Baratli J; Balakirski G; Megahed M
Hautarzt; 2014 Dec; 65(12):1011-3. PubMed ID: 25355498
[TBL] [Abstract][Full Text] [Related]
4. Tumor-associated M2 macrophages in mycosis fungoides acquire immunomodulatory function by interferon alpha and interferon gamma.
Furudate S; Fujimura T; Kakizaki A; Hidaka T; Asano M; Aiba S
J Dermatol Sci; 2016 Sep; 83(3):182-9. PubMed ID: 27342040
[TBL] [Abstract][Full Text] [Related]
5. Suppression of anti-interferon alpha-2a antibody formation in patients with mycosis fungoides by exposure to long-wave UV radiation in the A range and methoxsalen ingestion.
Kuzel TM; Roenigk HH; Samuelson E; Rosen ST
J Natl Cancer Inst; 1992 Jan; 84(2):119-21. PubMed ID: 1735877
[No Abstract] [Full Text] [Related]
6. Pharmacokinetic and pharmacodynamic characterization of a new formulation containing synergistic proportions of interferons alpha-2b and gamma (HeberPAG) in patients with mycosis fungoides: an open-label trial.
García-Vega Y; García-García I; Collazo-Caballero SE; Santely-Pravia EE; Cruz-Ramírez A; Tuero-Iglesias AD; Alfonso-Alvarado C; Cabrera-Placeres M; Castro-Basart N; Duncan-Roberts Y; Carballo-Treto TI; Soto-Matos J; Izquierdo-Toledo Y; Vázquez-Blomquist D; García-Iglesias E; Bello-Rivero I
BMC Pharmacol Toxicol; 2012 Dec; 13():20. PubMed ID: 23272809
[TBL] [Abstract][Full Text] [Related]
7. Peginterferon alfa-2b for mycosis fungoides.
Yanagi T; Shimizu T; Ujiie H; Ito M; Abe R; Tsuji-Abe Y; Hige S; Shimizu H
Arch Dermatol; 2006 May; 142(5):649-51. PubMed ID: 16702510
[No Abstract] [Full Text] [Related]
8. Interferon-alpha (INF-alpha) and etretinate in the treatment of mycosis fungoides.
Torii H; Kaneko T; Matsuyama T; Nakanishi H; Harada S
J Dermatol; 1994 Oct; 21(10):767-70. PubMed ID: 7798436
[TBL] [Abstract][Full Text] [Related]
9. The use of pegylated interferon a-2a in a cohort of Greek patients with mycosis fungoides.
Patsatsi A; Papadavid E; Kyriakou A; Georgiou E; Koletsa T; Avgeros C; Koumourtzis M; Lampadaki K; Tsamaldoupis A; Lazaridou E; Stratigos A; Nikolaou V
J Eur Acad Dermatol Venereol; 2022 Apr; 36(4):e291-e293. PubMed ID: 34753217
[No Abstract] [Full Text] [Related]
10. Mycosis fungoides in pregnancy: remission after treatment with alpha-interferon in a case refractory to conventional therapy: a case report.
Echols KT; Gilles JM; Diro M
J Matern Fetal Med; 2001 Feb; 10(1):68-70. PubMed ID: 11332424
[TBL] [Abstract][Full Text] [Related]
11. Cyclosporin A therapy for mycosis fungoides.
Jensen JR; Thestrup-Pedersen K; Zachariae H; Søgaard H
Arch Dermatol; 1987 Feb; 123(2):160-3. PubMed ID: 3813585
[No Abstract] [Full Text] [Related]
12. Clinical Trial of High-Dose Pegylated-Interferon-Alfa-2b Combined With Phototherapy in Advanced Stage Mycosis Fungoides.
Walker CJ; Espinosa ML; Mehta-Shah N; Pro B; Guitart J; Kuzel T
J Drugs Dermatol; 2021 Mar; 20(3):349-350. PubMed ID: 33683074
[TBL] [Abstract][Full Text] [Related]
13. Widespread comedones as the sole clinical manifestation of follicular mycosis fungoides.
Torres T; Velho G; Alves R; Selores M
Eur J Dermatol; 2010; 20(4):534-5. PubMed ID: 20413371
[No Abstract] [Full Text] [Related]
14. Intramuscular low dose alpha-2B interferon and etretinate for treatment of mycosis fungoides.
Altomare GF; Capella GL; Pigatto PD; Finzi AF
Int J Dermatol; 1993 Feb; 32(2):138-41. PubMed ID: 8440560
[TBL] [Abstract][Full Text] [Related]
15. Selective costimulation modulators of T cells: A potential treatment for mycosis fungoides and other SALT-proliferating diseases.
Capella GL
Med Hypotheses; 2007; 68(2):452. PubMed ID: 16919394
[No Abstract] [Full Text] [Related]
16. Poikilodermatous mycosis fungoides.
Farley-Loftus R; Mandal R; Latkowski JA
Dermatol Online J; 2010 Nov; 16(11):8. PubMed ID: 21163159
[TBL] [Abstract][Full Text] [Related]
17. Mycosis on mycosis fungoides: zoophilic dermatophytosis selectively superimposed on pre-existing cutaneous T-cell lymphoma (mycosis fungoides) plaques.
Capella GL; Altomare GF
Mycoses; 2003 Feb; 46(1-2):67-70. PubMed ID: 12588488
[TBL] [Abstract][Full Text] [Related]
18. Effective control of rush progression of CD8+ mycosis fungoides with pegylated interferon.
Fujimura T; Okuyama R; Hashimoto A; Watanabe H; Nakagawa S; Tagami H; Aiba S
Acta Derm Venereol; 2006; 86(2):161-2. PubMed ID: 16648924
[No Abstract] [Full Text] [Related]
19. The Use of Interferons in the Treatment of Cutaneous T-Cell Lymphoma.
Spaccarelli N; Rook AH
Dermatol Clin; 2015 Oct; 33(4):731-45. PubMed ID: 26433845
[TBL] [Abstract][Full Text] [Related]
20. [Interferon-alpha and PUVA therapy for mycosis fungoides].
Marschalkó M; Kovács J; Somlai B; Berecz M; Hídvégi B; Hársing J; Désaknai M; Horváth A
Orv Hetil; 2001 Sep; 142(37):2021-3. PubMed ID: 11582733
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
